Bulls vs Bears
Click to unlock major analysts' bullish and bearish positions by joining Benzinga Edge.
Comments
Loading...
Keros Therapeutics Analyst Ratings and Price Targets | NASDAQ:KROS | Benzinga
Keros Therapeutics Inc has a consensus price target of $25.3 based on the ratings of 16 analysts. The high is $65 issued by B of A Securities on July 26, 2023. The low is $15 issued by Wedbush on May 30, 2025. The 3 most-recent analyst ratings were released by B of A Securities, Wedbush, and Scotiabank on June 10, 2025, May 30, 2025, and May 12, 2025, respectively. With an average price target of $19.67 between B of A Securities, Wedbush, and Scotiabank, there's an implied 43.45% upside for Keros Therapeutics Inc from these most-recent analyst ratings.
Analyst Firms Making Recommendations1
B of A Securities
Wedbush
Scotiabank
HC Wainwright & Co.
Truist Securities
1calculated from analyst ratings
Analyst Ratings for Keros Therapeutics
| Buy Now | Get Alert | |||||||
|---|---|---|---|---|---|---|---|---|
| 06/10/2025 | Buy Now | 31.29% | B of A Securities | Jason Zemansky77% | $32 → $18 | Downgrade | Buy → Neutral | Get Alert |
| 05/30/2025 | Buy Now | 9.41% | Wedbush | Yun Zhong38% | $15 → $15 | Reiterates | Neutral → Neutral | Get Alert |
| 05/12/2025 | Buy Now | 89.64% | Scotiabank | Greg Harrison47% | $41 → $26 | Maintains | Sector Outperform | Get Alert |
| 05/08/2025 | Buy Now | 82.35% | HC Wainwright & Co. | Andrew Fein62% | $40 → $25 | Maintains | Buy | Get Alert |
| 04/09/2025 | Buy Now | 82.35% | Truist Securities | Srikripa Devarakonda45% | $43 → $25 | Maintains | Buy | Get Alert |
| 04/01/2025 | Buy Now | 9.41% | Wedbush | Yun Zhong38% | $15 → $15 | Reiterates | Neutral → Neutral | Get Alert |
| 04/01/2025 | Buy Now | 191.76% | HC Wainwright & Co. | Andrew Fein62% | $40 → $40 | Reiterates | Buy → Buy | Get Alert |
| 02/27/2025 | Buy Now | 89.64% | Wells Fargo | Tiago Fauth47% | $28 → $26 | Maintains | Overweight | Get Alert |
| 02/27/2025 | Buy Now | 191.76% | HC Wainwright & Co. | Andrew Fein62% | $47 → $40 | Maintains | Buy | Get Alert |
| 01/21/2025 | Buy Now | — | Cantor Fitzgerald | Prakhar Agrawal44% | — | Downgrade | Overweight → Neutral | Get Alert |
| 01/17/2025 | Buy Now | 9.41% | Piper Sandler | Joseph Catanzaro47% | $40 → $15 | Maintains | Overweight | Get Alert |
| 01/17/2025 | Buy Now | 9.41% | Wedbush | Andreas Argyrides70% | $47 → $15 | Downgrade | Outperform → Neutral | Get Alert |
| 01/17/2025 | Buy Now | — | Guggenheim | Vamil Divan74% | — | Reiterates | Neutral → Neutral | Get Alert |
| 01/16/2025 | Buy Now | 199.05% | Scotiabank | Greg Harrison47% | $44 → $41 | Maintains | Sector Outperform | Get Alert |
| 01/16/2025 | Buy Now | 67.76% | Oppenheimer | Andreas Argyrides70% | $63 → $23 | Maintains | Outperform | Get Alert |
| 12/23/2024 | Buy Now | 213.64% | Truist Securities | Srikripa Devarakonda45% | $100 → $43 | Maintains | Buy | Get Alert |
| 12/16/2024 | Buy Now | 359.52% | Oppenheimer | Andreas Argyrides70% | $102 → $63 | Maintains | Outperform | Get Alert |
| 12/16/2024 | Buy Now | — | Guggenheim | Vamil Divan74% | — | Downgrade | Buy → Neutral | Get Alert |
| 12/13/2024 | Buy Now | 104.23% | Wells Fargo | Tiago Fauth47% | $11 → $28 | Maintains | Overweight | Get Alert |
| 12/13/2024 | Buy Now | 220.93% | Scotiabank | Greg Harrison47% | $77 → $44 | Maintains | Sector Outperform | Get Alert |
| 12/13/2024 | Buy Now | 242.82% | HC Wainwright & Co. | Andrew Fein62% | $100 → $47 | Reiterates | Buy → Buy | Get Alert |
| 12/12/2024 | Buy Now | — | William Blair | Matt Phipps25% | — | Downgrade | Outperform → Market Perform | Get Alert |
| 12/12/2024 | Buy Now | — | TD Cowen | Tyler Van Buren44% | — | Downgrade | Buy → Hold | Get Alert |
| 12/12/2024 | Buy Now | — | BTIG | Julian Harrison37% | — | Downgrade | Buy → Neutral | Get Alert |
| 12/11/2024 | Buy Now | 709.63% | Wells Fargo | Tiago Fauth47% | $88 → $111 | Maintains | Overweight | Get Alert |
| 12/05/2024 | Buy Now | 643.98% | Guggenheim | Vamil Divan74% | $96 → $102 | Maintains | Buy | Get Alert |
| 12/04/2024 | Buy Now | — | Guggenheim | Vamil Divan74% | — | Reiterates | Buy → Buy | Get Alert |
| 11/22/2024 | Buy Now | — | Cantor Fitzgerald | Prakhar Agrawal44% | — | Reiterates | → Overweight | Get Alert |
| 11/07/2024 | Buy Now | 629.39% | HC Wainwright & Co. | Andrew Fein62% | $100 → $100 | Reiterates | Buy → Buy | Get Alert |
| 10/24/2024 | Buy Now | — | Cantor Fitzgerald | Prakhar Agrawal44% | — | Reiterates | → Overweight | Get Alert |
| 10/16/2024 | Buy Now | 461.63% | Scotiabank | Greg Harrison47% | → $77 | Initiates | → Sector Outperform | Get Alert |
| 09/23/2024 | Buy Now | 600.22% | Guggenheim | Vamil Divan74% | → $96 | Initiates | → Buy | Get Alert |
| 09/12/2024 | Buy Now | 454.34% | B of A Securities | Jason Zemansky77% | $81 → $76 | Maintains | Buy | Get Alert |
| 06/25/2024 | Buy Now | 643.98% | Oppenheimer | Andreas Argyrides70% | → $102 | Initiates | → Outperform | Get Alert |
| 06/18/2024 | Buy Now | 629.39% | Truist Securities | Srikripa Devarakonda45% | $100 → $100 | Maintains | Buy | Get Alert |
| 06/18/2024 | Buy Now | 629.39% | HC Wainwright & Co. | Andrew Fein62% | $100 → $100 | Reiterates | Buy → Buy | Get Alert |
| 05/09/2024 | Buy Now | 541.87% | Wells Fargo | Tiago Fauth47% | $77 → $88 | Maintains | Overweight | Get Alert |
| 05/09/2024 | Buy Now | 629.39% | HC Wainwright & Co. | Andrew Fein62% | $100 → $100 | Reiterates | Buy → Buy | Get Alert |
| 03/27/2024 | Buy Now | 665.86% | Piper Sandler | Joseph Catanzaro47% | → $105 | Maintains | Overweight | Get Alert |
| 03/13/2024 | Buy Now | 629.39% | Truist Securities | Srikripa Devarakonda45% | → $100 | Reiterates | Buy → Buy | Get Alert |
| 03/01/2024 | Buy Now | 629.39% | HC Wainwright & Co. | Andrew Fein62% | $100 → $100 | Reiterates | Buy → Buy | Get Alert |
| 02/29/2024 | Buy Now | 461.63% | Wells Fargo | Tiago Fauth47% | $60 → $77 | Maintains | Overweight | Get Alert |
| 12/08/2023 | Buy Now | 337.64% | Wells Fargo | Tiago Fauth47% | → $60 | Initiates | → Overweight | Get Alert |
| 11/13/2023 | Buy Now | 527.28% | Wedbush | Andreas Argyrides70% | → $86 | Reiterates | Outperform → Outperform | Get Alert |
| 08/31/2023 | Buy Now | 527.28% | Wedbush | Andreas Argyrides70% | → $86 | Reiterates | Outperform → Outperform | Get Alert |
| 08/09/2023 | Buy Now | 629.39% | HC Wainwright & Co. | Andrew Fein62% | → $100 | Reiterates | Buy → Buy | Get Alert |
| 08/08/2023 | Buy Now | 527.28% | Wedbush | Andreas Argyrides70% | → $86 | Reiterates | Outperform → Outperform | Get Alert |
| 08/07/2023 | Buy Now | 629.39% | HC Wainwright & Co. | Andrew Fein62% | → $100 | Reiterates | → Buy | Get Alert |
| 07/31/2023 | Buy Now | 527.28% | Wedbush | Andreas Argyrides70% | → $86 | Initiates | → Outperform | Get Alert |
| 07/26/2023 | Buy Now | 374.11% | B of A Securities | Greg Harrison47% | → $65 | Initiates | → Buy | Get Alert |
| 06/09/2023 | Buy Now | 629.39% | HC Wainwright & Co. | Andrew Fein62% | → $100 | Reiterates | → Buy | Get Alert |
| 05/08/2023 | Buy Now | 629.39% | HC Wainwright & Co. | Andrew Fein62% | → $100 | Reiterates | → Buy | Get Alert |
| 05/05/2023 | Buy Now | 702.33% | Piper Sandler | Joseph Catanzaro47% | $120 → $110 | Maintains | Overweight | Get Alert |
| 03/06/2023 | Buy Now | 629.39% | HC Wainwright & Co. | Andrew Fein62% | → $100 | Reiterates | → Buy | Get Alert |
| 02/14/2023 | Buy Now | — | Cowen & Co. | Tyler Van Buren44% | — | Initiates | → Outperform | Get Alert |
| 12/13/2022 | Buy Now | 665.86% | BTIG | Julian Harrison37% | $95 → $105 | Maintains | Buy | Get Alert |
| 10/18/2022 | Buy Now | 629.39% | Truist Securities | Srikripa Devarakonda45% | → $100 | Initiates | → Buy | Get Alert |
| 07/26/2022 | Buy Now | 483.52% | BTIG | Julian Harrison37% | → $80 | Initiates | → Buy | Get Alert |
FAQ
What is the target price for Keros Therapeutics (KROS) stock?
The latest price target for Keros Therapeutics (NASDAQ:KROS) was reported by B of A Securities on June 10, 2025. The analyst firm set a price target for $18.00 expecting KROS to rise to within 12 months (a possible 31.87% upside). 36 analyst firms have reported ratings in the last year.
What is the most recent analyst rating for Keros Therapeutics (KROS)?
The latest analyst rating for Keros Therapeutics (NASDAQ:KROS) was provided by B of A Securities, and Keros Therapeutics downgraded their neutral rating.
When was the last upgrade for Keros Therapeutics (KROS)?
There is no last upgrade for Keros Therapeutics
When was the last downgrade for Keros Therapeutics (KROS)?
The last downgrade for Keros Therapeutics Inc happened on June 10, 2025 when B of A Securities changed their price target from $32 to $18 for Keros Therapeutics Inc.
When is the next analyst rating going to be posted or updated for Keros Therapeutics (KROS)?
Analysts arrive at stock ratings after doing extensive research, which includes going through public financial statements, talking to executives and customers of Keros Therapeutics, and listening in to earnings conference calls. Most analysts do this every three months, so you should get 4 ratings per company per firm each year. The last rating for Keros Therapeutics was filed on June 10, 2025 so you should expect the next rating to be made available sometime around June 10, 2026.
Is the Analyst Rating Keros Therapeutics (KROS) correct?
While ratings are subjective and will change, the latest Keros Therapeutics (KROS) rating was a downgraded with a price target of $32.00 to $18.00. The current price Keros Therapeutics (KROS) is trading at is $13.65, which is out of the analyst’s predicted range.
Browse analyst ratings and price targets on all stocks.
